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Pesticide exposure has been associated with
acute and chronic adverse health effects. DNA methyl-
ation (DNAm) may mediate these effects. We evaluat-
ed the association between experiencing unusually
high pesticide exposure events (HPEEs) and DNAm
among pesticide applicators in the Agricultural Health
Study (AHS), a prospective study of applicators from
Iowa and North Carolina. DNA was extracted from
whole blood from male AHS pesticide applicators
(n5695). Questionnaire data were used to ascertain
the occurrence of HPEEs over the participant’s lifetime.
Pyrosequencing was used to quantify DNAm in
CDH1, GSTp1, and MGMT promoters, and in the
repetitive element, LINE-1. Linear and robust regres-
sion analyses evaluated adjusted associations
between HPEE and DNAm. Ever having an HPEE
(n5142; 24%) was associated with elevated DNAm
in theGSTp1 promoter at CpG7 (chr11:67,351,134;
P<0.01) and for the mean across the CpGs
measured in the GSTp1 promoter (P<0.01). In strati-
fied analyses, elevated GSTP1 promoter DNAm asso-
ciated with HPEE was more pronounced among
applicators >59 years and those with plasma folate
levels 16.56 ng/mL (p-interaction <0.01); HPEE
was associated with reducedMGMT promoter DNAm
at CpG2 (chr10:131,265,803; P50.03), CpG3
(chr10:131,265,810; P50.05), and the mean
across CpGs measured in the MGMT promoter (P5
0.03) among applicators >59 years and reduced
LINE-1 DNAm (P50.05) among applicators with
16.56 ng/mL plasma folate. Non-specific HPEEs
may contribute to increased DNAm in GSTp1, and in
some groups, reduced DNAm in MGMT and LINE-1.
The impacts of these alterations on disease develop-
ment are unclear, but elevated GSTp1 promoter
DNAm and subsequent gene inactivation has been
consistently associated with prostate cancer. Environ.
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INTRODUCTION
It is well-documented that farmers and agricultural
workers exposed to various pesticide classes and pesti-
cides currently on the market are at increased risk for
certain cancers, including leukemia, multiple myeloma,
non-Hodgkin lymphoma (NHL), and prostate cancer
[Blair et al., 1985; Hoar et al., 1986; Blair and Zahm,
1991; Brown et al., 1993; Zahm et al., 1993; Dich and
Wiklund, 1998; Alavanja et al., 2003]. The biological
mechanisms underlying this increased risk are incom-
pletely understood [Alavanja et al., 2004; Alavanja and
Bonner, 2005; Jaga and Dharmani, 2005; Alavanja et al.,
2013a,b]. Multiple mechanisms are likely involved. Direct
genotoxicity is an important mechanism but non-
genotoxic mechanisms could be operating as well. Some
suspected, non-genotoxic mechanisms described in the lit-
erature include oxidative stress and receptor-mediated
toxicities [De Coster and van Larebeke, 2012; Sesti et al.,
2012; Alavanja et al., 2013a,b]. There is emerging evi-
dence that epigenetic mechanisms may also play an
important role in pesticide-related carcinogenesis, based
on findings in experimental studies [Tao et al., 2000; Das
and Singal, 2004; Anway et al., 2005; Laird, 2005;
Anway and Skinner, 2006; Skinner and Anway, 2007;
Guerrero-Bosagna et al., 2012; Zhang et al., 2012],
however, there have been very few human studies to date
which have investigated this link.
Epigenetic mechanisms involve heritable changes in
phenotype or gene expression that do not result from
changes in the primary DNA sequence. An epigenetic
mechanism, DNA methylation (DNAm), is a process of
adding a methyl group to DNA via DNA methyltransfer-
ase; it influences gene expression and is linked to both
transcriptional silencing and activation. Alterations in
DNAm are recognized as key epigenetic changes in can-
cer [Bremnes et al., 2005; Kerr et al., 2007], and it is
hypothesized that cells with aberrant DNAm acquire an
overall gene expression pattern that favors proliferation
and differentiation, leading to neoplastic transformation
[Moore et al., 2003]. There is a paucity of evidence eval-
uating alterations in DNAm associated with exposure to
pesticides. Most studies to date have been carried out in
experimental animals or in human cell lines [Tao et al.,
2000; Das and Singal, 2004; Anway et al., 2005; Laird,
2005; Anway and Skinner, 2006; Skinner and Anway,
2007; Guerrero-Bosagna et al., 2012; Zhang et al., 2012;
Collotta et al., 2013]. The few human studies published
have focused on persistent organic pollutants [Rusiecki
et al., 2008; Kim et al., 2010; Lind et al., 2013] and arse-
nic [Pilsner et al., 2007, 2009; Chervona et al., 2012;
Tajuddin et al., 2013]. We had the opportunity to evaluate
epigenetic patterns potentially associated with pesticide
exposure in a subgroup of pesticide applicators from a
large cohort study, the Agricultural Health Study (AHS).
High pesticide exposure events (HPEEs), self-reported
incidents of unusually high, non-specific exposure to pes-
ticides, fertilizers, or other chemicals, are common within
the agricultural community. HPEEs typically result from
spills and other accidents and can involve high acute pes-
ticide exposures; they are sometimes associated with vari-
ous acute and chronic symptoms [Ogilvie et al., 1990]. In
the AHS cohort at the time of enrollment, 14% of
licensed pesticide applicators reported having at least one
HPEE in their working lifetime [Alavanja et al., 1999].
Although the majority (87%) of these HPEE reports did
not result in a health care visit [Bell et al., 2006], HPEEs
may involve toxicologically and mechanistically relevant
pesticide exposures, and long-term adverse health effects
may result from pesticide exposures at levels associated
with these events [O’Malley, 1997; Alavanja et al.,
1999].
In this study we evaluate the association between
HPEEs and levels of DNAm in blood in a population of
male pesticide applicators [Starks et al., 2012a,b]. We
focused on critical target loci within genes whose
expression is regulated by DNAm, E-cadherin (CDH1),
glutathione-S-transferase-p1 (GSTP1), and O6-alkylguanine-
DNA alkyltransferase (MGMT). These genes are commonly
found to be aberrantly methylated in cancers which have
been found to have positive associations with specific pesti-
cides in the AHS, including lymphohematopoietic cancers,
prostate cancer, and lung cancer [Melki et al., 1999; Goessl
et al., 2002; Jeronimo et al., 2002; Jeronimo et al., 2002;
Esteller, 2003; Nagasaka et al., 2003; Chim et al., 2004;
Ekmekci et al., 2004; Kang et al., 2004; Rossi et al., 2004;
Seidl et al., 2004; Bastian et al., 2005; Enokida et al., 2005;
Hoque et al., 2005; Russo et al., 2005; Aggerholm et al.,
2006; Gu et al., 2006; Nakata et al., 2006; Papadopoulou
et al., 2006; Chuang et al., 2007; Alavanja et al., 2013a,b].
We also evaluated DNAm in a repetitive element, long
interspersed nucleotide element (LINE-1), since reduced
DNAm of LINE-1 may indicate chromosomal instability
[Rothenberg et al., 1972].
MATERIALS ANDMETHODS
Study Population
The AHS is a prospective cohort study that includes 57,310 private
and commercial applicators licensed to apply restricted use pesticides in
Iowa or North Carolina at the time of enrollment (1993–1997) [Alavanja
et al., 1996]. Each participant completed a self-administered enrollment
questionnaire, and 44% of the cohort also completed a “take home”
questionnaire within one month of enrollment. The enrollment and take
home questionnaires (1993–1997) comprised Phase 1 of the data collec-
tion. Two follow-up phone interviews were administered to the study
participants at approximately 5-year intervals (1999–2003, 2005–2010),
comprising Phases 2 and 3 of the data collection. The questionnaires
from each phase of the study included questions about HPEEs.
A random sample of AHS applicators who completed all three phases of
data collection was recruited (n5 1,807) for a study of neurobehavioral
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outcomes and multiple pesticide exposure metrics, including HPEEs
[Starks et al., 2012a,b]. The study population was chosen based on lifetime
use of organophosphate pesticides (OPs). Specifically, a stratified random
sample was selected from eligible AHS participants with equal sampling
from the upper 25% and the lower 75% of the distribution of lifetime OP
pesticide use [Starks et al., 2012a,b]. AHS participants who had reported a
stroke, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s dis-
ease, retinal or macular degeneration, hypothyroidism, diabetes, or who
were excessive drinkers were not included in the study [Starks et al.,
2012a,b].
Whole blood samples collected at the time of neurobehavioral testing
were used in the current study for extraction of DNA and quantification
of DNAm. Of the total 701 applicators included in the neurobehavioral
outcomes study, 693 did not report a past physician-diagnosed pesticide
poisoning event. Of those, 598 were cancer-free and provided a whole
blood sample. For two samples, we were unable to measure DNA meth-
ylation. The final number of applicators included in this study was 596.
This study was approved by the Institutional Review Boards of the
National Institutes of Health, the University of Iowa, Harvard Universi-
ty, and the Uniformed Services University.
High Pesticide Exposure Event Assessment
Data on ever having an HPEE was based on the AHS questionnaires
and was not specific to particular pesticides or other exposures. Each phase
assessed HPEE somewhat differently, using the following questions:
Phase 1: Have you ever had an incident or experience while using any
type of pesticide which caused you unusually high personal exposure?
Phase 2: Since (year of enrollment) did you have any incidents with
fertilizers, herbicides, or other pesticides that caused you an unusually
high personal exposure?
Phase 3: Since (date of last interview) have you had any incidents or
spills that resulted in an unusually high exposure to pesticides from contact
with your skin, from breathing fumes or dust, or from accidental ingestion?
Information regarding HPEEs was obtained prior to blood collection,
thus providing a prospective design for the current study. Based on the
HPEE data collected in the three phases, a metric of having ever reported
an HPEE was constructed; if an applicator answered “yes” to having an
HPEE in at least one of the three phases, they were considered to have ever
reported an HPEE.
DNAmQuantification
DNA was extracted from whole blood using the QIAamp DNA blood
mini/maxi kit (Qiagen, MD, USA). One microgram of genomic DNA
was used for bisulfite conversion. The bisulfite-modified DNA was then
amplified using PCR primers that flank the target CpGs. The biotinylated
PCR primer enabled selection of one strand for pyrosequencing reaction.
The single strand biotinylated PCR products were then pyrosequenced
using a sequencing primer to measure the DNA methylation from the
target CpGs. We performed bisulfite conversion using the EZ DNA
Methylation-GoldTM Kit (Zymo Research, CA) followed by pyrose-
quencing using the PSQ Q96 MD Pyrosequencing system (QIAGEN,
Valencia, CA) platform. Samples were run in duplicate and internal con-
trols used to assess the efficiency of the bisulfite-conversion treatment.
Samples with conversion efficiency <95% were excluded from down-
stream analysis. The degree of methylation at each CpG within the PCR
amplicon was analyzed individually or as an average over the multiple
CpG sites. The degree of methylation is expressed here as the percent-
age of methylated cytosines divided by the sum of methylated and
unmethylated cytosines (%5mC), which we refer to throughout this
paper as DNAm. For the purpose of quality control, we included dupli-
cate samples (6% of the total number of samples) to which the
laboratory was blinded.
We measured DNAm at individual CpG lioci promoter regions of:
CDH1, GSTp1, and MGMT. For CDH1 we measured DNAm at three
CpG sites (CpG#1: chr16:68,770,944; CpG#2: chr16:68,770,947;
CpG#3: chr16:68,770,960), for GSTp1 we measured 10 CpG sites (CpG
#1: chr11:67,351,089; CpG #2: chr11:67,351,099; CpG #3: chr11:
67,351,101; CpG #4: chr11:67,351,104; CpG #5: chr11:67,351,110; CpG
#6: chr11:67,351,124; CpG #7: chr11:67,351,134; CpG #8: chr11:67,
351,138; CpG #9: chr11:67,351,141; CpG #10: chr11:67,351,145), and
for MGMT we measured three CpG sites (CpG #1: chr10:131,265,796;
CpG #2: chr10:131,265,803; CpG #3: chr10:131,265,810). To quantify
promoter methylation, we used methods previously described for CDH1
[Avila et al., 2010; Kordi-Tamandani et al., 2010], GSTp1 [Ronneberg
et al., 2008; Peng et al., 2009], and MGMT [Cheng et al., 2006]. Details
of the promoters, amplicons, primers, and sequences analyzed are pre-
sented in Supporting Information Table 1. For the repetitive element,
LINE-1 we measured DNAm at four loci. To quantify methylation in the
repetitive element, LINE-1, we used methods described by Yang et al.
[2004]
Plasma Folate and Vitamin B12
Because DNAm is influenced by folate and vitamin B12, micronu-
trients involved in 1-carbon metabolism, we measured plasma levels of
folate and vitamin B12 in all participants. This was a one-time measure-
ment, made in the same sample as the whole blood used as a source of
DNA. For plasma folate, we used an assay commonly used for clinical
use [Rothenberg et al., 1972]. Plasma vitamin B12 was measured by a
quantitative sandwich enzyme immunoassay technique on the 2010
Elecsys Immunoanalyzer (Roche Diagnostics) [Rothenberg, 1961]. All
plasma folate and B12 measurements were carried out at the Clinical &
Epidemiologic Research Laboratory, in the Department of Laboratory
Medicine, at Children’s Hospital, Boston. Units for plasma folate and
B12 were reported in ng/mL and pg/mL, respectively.
Statistical Analysis
For the three genes (CDH1, GSTp1, and MGMT), we analyzed associa-
tions between HPEE and DNAm at individual promoter CpG loci. Because
the GSTp1 promoter typically has low levels of methylation, and the mar-
gin of detection/error for measurement of percent methylation is generally
in the range of 3-6%, we limited our analyses of GSTp1 to observations
with levels of methylation greater than 6%. For the repetitive element,
LINE-1 we evaluated the mean of the four CpGs measured.
We calculated intra-class correlation coefficients (ICCs) for each
CpG locus and for the average of four CpG sites in LINE-1 loci, based
on blinded duplicates randomly arranged in the plates run for this study
(6% of total sample were included as duplicates). ICCs ranged between
0.61 and 0.78 for the CpG sites measured in CDH1, 0.57 to 0.74 for
CpG sites measured in MGMT, and 0.45 and 0.66 for CpG sites mea-
sured in GSTp1. For LINE-1, the ICC for the mean across four CpG
sites was 0.40, but the coefficient of variation (CV) was very low (3%).
We visually evaluated distribution plots for all DNAm loci measured.
Visual inspection of plots for CpG sites in the promoters of CDH1 and
MGMT loci, as well as DNAm in LINE-1 indicated normal distribution;
visual inspection of plots for CpG sites in the GSTp1 promoter, howev-
er, indicated a non-normal distribution. Therefore, we utilized t-tests to
compare DNAm levels between applicators reporting ever and never
having an HPEE across the three phases of the AHS study for CDH1,
MGMT, and LINE-1 and Wilcoxon Rank Sum tests to compare the
DNAm levels in GSTp1.
We evaluated a common set of covariates, potentially associated with
DNAm or with HPEE, for confounding: age at blood draw (continuous),
race, state of residence (Iowa or North Carolina), education, consumption of
fruits and vegetables, alcohol consumption, years lived on a farm, body mass
index (BMI), smoking, ever use of personal protective equipment, skin
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sensitivity to sun exposure, and still living on a farm (Phase 3). We also
included plasma levels of vitamin B12 and folate in our evaluation for con-
founding, because both these dietary nutrients are required to maintain 1 car-
bon pools for normal homocysteine remethylation, S-adenosyl methionine
(SAM) formation, and DNA methylation [Shin et al., 2010; Crider et al.,
2012].
We first evaluated the unadjusted association between each covariate
and each methylation marker, based on the mean of the CpG sites in
that marker (e.g., CDH1, MGMT, GSTp1, and LINE-1), using linear
regression. We then evaluated the unadjusted association between each
covariate and HPEE (binary variable—ever/never), using logistic regres-
sion. Covariates associated with both a methylation marker and HPEE
based on a P-value of <0.20 were subsequently selected for inclusion
into an initial full multiple linear regression base model for that marker.
Using a backwards regression, we then removed covariates from the
initial full base model if they had a P-value of 0.20. The final base
model for each methylation marker included only those covariates with
a P-value <0.20. Based on our backwards regression models, the follow-
ing variables were included into final models: CDH1: drinks per month
of alcohol and skin sensitivity to sun; for MGMT: pack years in Phase 1
and having personally mixed, loaded, or applied pesticides in Phase 3;
for GSTp1: no covariates met the inclusion criteria; LINE-1: Still living
on a farm in Phase 3. However, we included age as a continuous vari-
able into all final models because of its relevance with DNA methylation
patterns in blood cells and likelihood of having an HPEE.
We estimated adjusted associations between CDH1, MGMT, and
LINE-1 DNAm and HPEE using linear regression models in which the
outcome (DNAm) was regressed on ever having an HPEE, adjusting for
the base model covariates. For GSTp1, because the residuals were not
normally distributed, even after various transformations, we employed a
robust regression analysis [Lawrence and Arthur, 1990] to evaluate the
associations between DNAm in GSTp1 and HPEE. We further evaluated
this association using bootstrapping and quantile regression analyses.
Sensitivity Analyses
For the primary analyses described above, we analyzed data from all
participants. To evaluate the robustness of our results, we conducted two
sensitivity analyses where we evaluated results from (1) non-smokers
and (2) people with a greater than high school education. Our assump-
tion was that if these subgroups of our study population showed internal
consistency, then our results for the overall population could be consid-
ered more robust. We also checked if there was internal consistency by
state residence (Iowa and North Carolina).
Stratified Analyses
We carried out a series of stratified analyses to investigate the poten-
tial for effect modification from age, plasma folate, and plasma B12. We
adjusted stratified analyses by age at blood draw (cut at the median; 59
years), plasma folate levels (cut at the median; 16.56 ng/mL), and vita-
min B12 levels (cut at the median; 585.95 ng/mL). We used the same
adjusted linear regression analyses for CDH1, MGMT, and LINE-1 and
the same adjusted robust regression analyses for GSTp1 as described
above and calculated a P-value for interactions.
We used the P1RE1071201, P2RE1071202, and P3RE10901 releases
of the AHS dataset. All analyses were performed using SAS software,
version 9.2 (SAS Institute, Cary, NC).
RESULTS
A total of 142 (24%) of the 596 men in this sample
reported an HPEE in any of the three phases of the AHS.
Characteristics of the study population stratified by ever
reporting an HPEE in any of the three phases of the AHS
are presented in Table I. Applicators reporting ever
having had an HPEE were younger at blood draw (mean-
5 56.9; s.d.510.7) than those who never experienced an
HPEE (mean5 60.9; s.d.511.5). Sixty-four percent of
applicators with an HPEE had greater than a high school
education compared to 49% of those without an HPEE.
Applicators who reported an HPEE also reported more
total lifetime days of application of any pesticides (mean-
5 2,005.31; s.d.51,829.66) compared with those who
reported never having an HPEE (mean5 1,452.16;
s.d.51,544.84). Despite these differences, age, education,
and lifetime days pesticide application did not meet the
criteria for confounders and thus inclusion in regression
models. However, as mentioned above, we included age
as a continuous variable into all final models because of
its relevance with DNA methylation patterns in blood
cells and likelihood of having an HPEE.
Student’s t-tests and Wilcoxon rank sum tests, comparing
DNAm at each locus between applicators reporting ever
and never having an HPEE across the three phases of the
AHS study are presented in Table II. As described above,
for GSTp1 we limited our analyses to observations with
greater than 6% DNAm. This resulted in small sample sizes
for CpGs 1, 3, 4, and 5. We therefore present results only
for CpGs 2, 6, 7, 8, 9, and 10. We found no statistically sig-
nificant differences via t-tests for DNAm in CDH1, MGMT,
and LINE-1 between applicators reporting an HPEE and
those not reporting an HPEE. We found via Wilcoxon rank
sum test that those reporting ever having an HPEE had
higher DNAm at GSTp1 CpG 7 (chr11:67,351,134; mean-
5 11.96 (s.d.5 7.95); median5 9.74) than those never
reporting an HPEE (mean5 9.82 (s.d.5 5.04);
median5 7.92); P5 0.02. There were also non-statistically
significant higher DNAm levels for those reporting an HPEE
compared with those who did not at GSTp1 CpGs
8 (chr11:67,351,138), 9 (chr11:67,351,141) and 10
(chr11:67,351,145). The mean DNAm of CpGs
2,6,7,8,9,10 in GSTp1 was significantly higher for those
reporting an HPEE (mean5 14.57 (s.d.5 8.76)
median5 11.40) than for those not reporting an HPEE
(mean5 8.90 (s.d.5 3.18) median5 7.96); P< 0.01.
We detected no statistically significant associations
between HPEE and DNAm in CDH1, MGMT, and LINE-
1 via adjusted linear regression analyses (Table III). The
results of adjusted robust regression analyses for GSTp1
CpGs are presented in Table IV. We found a statistically
significant elevation of DNAm for GSTp1 CpG 7
(b5 2.07; P< 0.01) and for the mean across six CpGs
measured in the promoter (b5 2.68; P< 0.01); applica-
tors ever having an HPEE had, on average, over 2%
higher DNAm than those without an HPEE. We also
found a non-significant positive association of a similar
magnitude for GSTp1 CpG 8 (b5 1.98; P5 0.06). Results
from bootstrapping analyses and quantile regression
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analyses for GSTp1 yielded similar results (data not
shown). In sensitivity analyses, when we restricted our
population to non-smokers and those with at least a high
school education, we saw no meaningful differences in
the results of our linear regression analyses or robust
regression analyses compared to analyses including the
total study population (data not shown). Additionally, pat-
terns were similar for residents of both Iowa and North
Carolina.
In adjusted linear regression-based stratified analyses
for CDH1, MGMT, and LINE-1 (Supporting Information
Table 2), we found that among applicators older than the
median age (59 years) at blood draw, there were statisti-
cally significant associations of HPEE with reduced
DNAm for MGMT CpG 2 (chr10:131,265,803; b5
23.59; P5 0.03), CpG3 (chr10:131,265,810; b522.55;
P5 0.05), and for the mean across the three MGMT
CpGs measured (b522.68; P5 0.03). In contrast there
were only non-significant, weakly positive estimates for
younger applicators. Tests for interaction of age by HPEE
were statistically significant for MGMT CpG 2 (P5 0.02)
and the mean across the promoter’s three CpGs
TABLE I.General Characteristics of Study Population
Characteristic
Never had an HPEE (n5 454) Ever had an HPEE(n5 142)
Mean SD N % Mean SD N %
Age at blood draw 60.91 (11.46) 454 56.87 (10.71) 142
Categorized Age at blood draw
30–40 15 3.30 8 5.63
>40–50 65 14.32 25 17.61
>50–60 142 31.28 64 45.07
>60–70 127 27.97 29 20.42
>70–80 82 18.06 11 7.75
>80 23 5.07 5 3.52
Testing location
Iowa 229 (50.44) 74 (52.11)
North Carolina 225 (49.56) 68 (47.89)
Race
White 431 (97.51) 138 (99.28)
Black 7 (1.58) 1 (0.72)
Other 4 (0.90) 0 (0.00)
Missing 12 3
Education
High school 220 (50.93) 50 (35.97)
>High school 212 (49.07) 89 (64.03)
Missing 22 3
Personal protective Equipment Use
No 67 (14.76) 20 (14.08)
Yes 387 (85.24) 122 (85.92)
Alcohol Use in the last year (Phase 3)
No 172 (37.89) 45 (31.91)
Yes 282 (62.11) 96 (68.09)
Alcohol consumption (drinks/week) (Phase 3)
None 172 (37.89) 45 (31.91)
Daily 28 (6.17) 16 (11.35)
Weekly 114 (25.11) 34 (24.11)
Monthly 73 (16.08) 21 (14.89)
< 1 time per month 67 (14.76) 25 (17.73)
Total Lifetime Days of Pesticidesa 1,452.16 (1544.84) 2,005.31 (1829.66)
Plasma Vitamin B12 637.80 (307.50) 668.40 (312.40)
Plasma Folate 19.19 (9.62) 18.59 (8.51)
Body Mass Index at Enrollment 27.16 (3.67) 27.13 (3.69)
Body Mass Index at Phase 3 28.45 (4.17) 28.65 (4.43)
Pack years smoked at
Enrollment (Phase 1)
8.65 (17.55) 6.47 (13.05)
Years smoked at Enrollment (Phase 1) 7.43 (11.09) 6.16 (10.52)
Number of cigarettes smoked
per day (Phase 3)
6.56 (9.16) 6.78 (10.10)
Vegetable servings per month (Phase 1) 5.01 (1.88) 5.31 (1.87)
Fruit servings per month (Phase 1) 3.55 (1.72) 3.76 (1.88)
aSummed across Phases 1-3 of the Agricultural Health Study.
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(P5 0.05). We also found statistically significant reduced
DNAm in LINE-1 among responders with less than or
equal to the median, 16.56 ng/mL plasma folate levels
(b520.70; P5 0.05) and no associations among those
with higher than the median plasma folate levels; howev-
er, the test for interaction p-value was 0.13. In analyses
stratified by plasma levels of vitamin B12 we found no
significant differences between strata for associations
between HPEE and CDH1, MGMT, and LINE-1 DNAm.
In adjusted robust regression-based stratified analyses for
GSTp1 (Supporting Information Table 2), we found mixed
results after stratifying by age, folate, and vitamin B12. In
analyses stratified by age, HPEE was significantly associat-
ed with increased DNAm at CpG 6 (b5 12.83; P< 0.01)
and CpG 9 (b5 2.24; P5 0.02) in younger but not older
applicators, with statistically significant p-interactions
(0.03, <0.01, respectively). However, in older applicators
HPEE was non-significantly associated with increased
DNAm for in CpGs 2, 7, 8, and 10, resulting in significantly
increased DNAm for the mean across CpGs in GSTp1
(b5 5.65; P< 0.01). Associations were not significant in
younger applicators, and the P-value for interaction of
age by HPEE was significant (P< 0.01). Similar, mixed
patterns by individual CpGs were found after stratifications
by folate, but HPEE was associated with greater methyla-
tion for the mean across CpGs, HPEE was associated with
greater DNAm among those with plasma folate 16.56 ng/
mL (b5 13.74; P< 0.01), than among those with plasma
folate >16.56 (b5 2.90; P< 0.01); p-interaction< 0.01.
For vitamin B12, effects for individual CpGs were not very
strong, but for the mean across CpGs HPEE was
significantly associated with increased DNAm for those
with higher than the median plasma level of 585.95 ng/mL
(b5 2.85; P5 0.02) but not for those with lower B12; p-
interaction was marginally significant (P5 0.09).
DISCUSSION
In this study, we found that ever having an HPEE was
significantly associated with elevated DNAm for GSTp1
promoter CpG 7 (P< 0.01) and the mean across CpGs
measured in the GSTp1 promoter (P< 0.01). GSTp1 pro-
moter DNAm was elevated particularly among applicants
who were older (>59 years at blood draw), and those
with lower plasma folate levels (16.56 ng/mL) (median)
plasma folate levels. MGMT promoter DNAm was
reduced for CpG2 (P5 0.03), CpG3 (P5 0.05), and the
mean across CpGs measured in the MGMT promoter
(P5 0.03) among older applicators only. LINE-1 DNAm
was lower (P5 0.05) among applicators who had 16.56
ng/mL plasma folate levels only.
The genes we focused on in this study are potentially
relevant to disease processes associated with exposure to
pesticides. GSTp1 is a member of a family of enzymes
involved in DNA protection from electrophilic metabo-
lites of carcinogens and reactive oxygen species (ROS)
[Henrique and Jeronimo, 2004). It is commonly hyperme-
thylated in prostate cancer [Goessl et al., 2002; Jeronimo
et al., 2002; Jeronimo et al., 2002; Kang et al., 2004;
Bastian et al., 2005; Enokida et al., 2005; Hoque et al.,
2005; Papadopoulou et al., 2006; Chuang et al., 2007]
and has been reported to be hypermethylated in B-cell
TABLE II.Comparison of Mean Levels of %5-mC (DNAm) at Each Locus Measured Between pesticide applicators Ever and
Never Reporting an HPEE
DNAm Locus
Never had an HPEE Ever had an HPEE
P-valueN Mean SD Median N Mean SD Median
CDH1 CpG 1 (chr16:68,770,944) 430 26.57 (9.14) 26.11 136 25.56 (10.78) 25.33 0.33
CDH1 CpG 2 (chr16:68,770,947) 429 25.65 (8.88) 25.38 136 25.07 (14.42) 23.96 0.66
CDH1 CpG 3 (chr16:68,770,960) 430 15.85 (7.43) 14.86 136 15.55 (8.95) 14.06 0.72
CDH1 Mean CpG 1-3 430 22.71 (6.62) 22.48 136 22.06 (9.38) 21.69 0.45
GSTp1 CpG 2 (chr11:67,351,099) 82 8.99 (3.07) 8.02 24 8.62 (3.34) 6.90 0.29#
GSTp1 CpG 6 (chr11:67,351,124) 81 11.24 (7.29) 7.90 23 13.04 (9.38) 9.47 0.29#
GSTp1 CpG 7 (chr11:67,351,134) 70 9.82 (5.04) 7.92 21 11.96 (7.95) 9.74 0.02#**
GSTp1 CpG 8 (chr11:67,351,138) 64 10.93 (7.05) 8.19 15 14.67 (9.34) 13.04 0.12#
GSTp1 CpG 9 (chr11:67,351,141) 40 10.32 (7.07) 7.85 8 14.89 (13.20) 9.93 0.09#
GSTp1 CpG 10 (chr11:67,351,145) 91 12.12 (8.84) 8.76 19 18.99 (22.34) 11.95 0.07#
GSTp1 Mean CpG 2,6-10 76 8.90 (3.18) 7.96 13 14.57 (8.76) 11.40 <0.01#**
MGMT CpG 1 (chr10:131,265,796) 445 25.15 (8.18) 24.03 139 24.93 (9.15) 24.62 0.79
MGMT CpG 2 (chr10:131,265,803) 444 37.73 (9.32) 37.49 139 37.33 (10.35) 37.50 0.66
MGMT CpG 3 (chr11:131,265,810) 443 16.33 (7.60) 14.87 139 15.33 (7.50) 15.10 0.18
MGMT Mean CpG 1-3 445 26.42 (7.27) 25.60 139 25.86 (7.85) 25.29 0.44
Line 1 Mean (CpG 1-4) 447 78.43 (2.48) 78.29 141 78.42 (2.83) 78.15 0.95
#Wilcoxon rank-sum test p-value - for GSTp1 loci only.
**Indicates t-test P-value <0.05.
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malignancies [Rossi et al., 2004] and leukemia [Melki
et al., 1999]. We found elevated DNAm (hypermethyla-
tion) of the GSTp1 promoter DNAm for pesticide applica-
tors who experienced an HPEE compared with those who
never experienced an HPEE across the three phases of
the AHS. These elevations were more pronounced for
older applicators and those with lower plasma folate lev-
els measured at the same time DNAm was measured. Sta-
tistically significant interactions for various loci in the
GSTp1 promoter may indicate effect modification by age
and by plasma folate levels. Restricting our analysis to
DNAm 6% for the sake of minimizing measurement
error, reduced our sample size, however, the distributions
of HPEE and other baseline characteristics, were similar
between those in the <6% range of GSTp1 DNAm and
those with levels 6%.
MGMT is a DNA repair protein that removes mutagen-
ic and cytotoxic adducts from 06-guanine in DNA. The
MGMT protein is widely regarded as a major contributor
to the protection of cells against the mutagenic, carcino-
genic, and cytotoxic effects of DNA-alkylating agents
[Nagasaka et al., 2003]. Our study found that among
older applicators (those greater than 59 years) only, CpG
sites 2 and 3 and the mean of the three CpGs in the
MGMT promoter had lower DNAm levels (hypomethyla-
tion) for those with an HPEE compared to those without
an HPEE. Thus, age is potentially an effect modifier in
the association between HPEE and MGMT DNAm.
CDH1, a member of the cadherin family of adhesion
molecules, acts as a tumor and invasion suppressor, the
loss of which has been associated with tumorigenesis and
increased metastatic potential. It has been found to be
hypermethylated in leukemia [Ekmekci et al., 2004;
Aggerholm et al., 2006], multiple myeloma [Chim et al.,
2004; Seidl et al., 2004], other blood neoplasms [Esteller,
2003], lung cancer [Russo et al., 2005; Gu et al., 2006;
Nakata et al., 2006] and prostate cancer [Hoque et al.,
2005]. We did not find differences in CDH1 DNAm lev-
els between applicators with and without an HPEE.
The repetitive element, LINE-1, has been found to be
hypomethylated in the blood of cancer patients [Barchitta
et al., 2014]. LINE-1 hypomethylation has also been asso-
ciated with elevated serum levels of some pesticides,
namely chlorinated hydrocarbons [Rusiecki et al., 2008;
Kim et al., 2010]. In this study, we found that there was
an inverse association between HPEE and LINE-1 DNAm
(e.g., reduced DNAm/hypomethylation) among applica-
tors in the low plasma folate group only. Folate deficien-
cy has been associated with chromosomal damage in
human lymphocytes in vitro and in human lymphocytes
and buccal cells in vivo [Crott et al., 2001], and low die-
tary intake of folate can contribute to cancer risk by
demethylation of DNA due to uracil misincorporation
during DNA synthesis [Herbert, 1986]. Prior studies have
shown that low folate levels can affect susceptibility to
disease from exposures, such as As, where the odds of
As-related skin lesions were higher among individuals
with low folate [Pilsner et al., 2007, 2009].
In this study, our focus was on HPEE, which likely
represents acute, high pesticide exposure. It is not clear
whether any observed effects result directly from the
HPEE, or whether HPEE may serve as a surrogate for
having work practices or characteristics that might lead to
overall higher pesticide exposures over time. Applicators
who reported a history of physician-diagnosed pesticide
poisoning were excluded from the study population, so
HPEE is not a surrogate for poisoning. The prevalence of
HPEE across the three phases of the AHS study in the
study sub-population was higher (24%) than in the AHS
TABLE III.Adjusted* Linear Regression Analyses Evaluating
the Association Between an HPEE and %5-mC (DNAm) in
CDH1, MGMT, and LINE-1
Ever HPEE across 3 phases
Gene CpG N b P-value
CDH1 CpG 1 (chr16:68,770,944) 535 20.55 0.57
CpG 2 (chr16:68,770,947) 534 20.63 0.56
CpG 3 (chr16:68,770,960) 535 0.16 0.85
Mean CpG 1-3 535 20.36 0.64
MGMT CpG 1 (chr10:131,265,796) 553 20.54 0.53
CpG 2 (chr10:131,265,803) 552 20.62 0.53
CpG 3 (chr11:131,265,810) 551 21.08 0.16
Mean CpG 1-3 553 20.78 0.30
LINE-1 mean 476 20.23 0.39
*Models adjusted for variables as described below:.
CDH1 adjusted for age at blood draw (continuous), drinks per month of
alcohol, and skin sensitivity to sun.
MGMT adjusted for age at blood draw (continuous), pack years in Phase
1, and personally mixed, loaded, or applied pesticides in Phase 3.
LINE-1 adjusted for age at blood draw (continuous), and still living on a
farm in Phase 3.
TABLE IV.Adjusted* Robust Regression Analyses Evaluating
the Association Between an HPEE and %5-mC (DNAm) in
GSTp1
Ever HPEE across 3 phases
CpG N
Robust Regression
Estimate (b) P-value
GSTP1 CpG2 106 20.83 0.12
GSTP1 GpG6 104 0.58 0.40
GSTP1 CpG7 91 2.07 <0.01**
GSTP1 CpG8 79 1.98 0.06
GSTP1 CpG9 48 0.97 0.27
GSTP1 CpG10 110 1.35 0.14
GSTp1 Mean
(CpG 2,6,7,8,9,10)
89 2.68 <0.01**
*Adjusted for age at blood draw (continuous).
**indicates Robust Regression P-value <0.05.
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population which did not participate in this study (15%)
[Starks et al., 2012a,b], because of the sampling method-
ology used to recruit applicators for the study. Since
applicators were sampled equally from those in the upper
25% and the lower 75% of the distribution of lifetime
days of organophosphate pesticide use, this higher propor-
tion with an HPEE is not unexpected, since HPEE is
more prevalent among those with greater lifetime days of
pesticide exposure.
Various mechanisms may alter DNA methylation pat-
terns from exposure to pesticides which have been found
to result in increased carcinogenic risk, including oxida-
tive stress induction (ROS generation), alkylation of
DNA, acetylcholinesterase (AChE) inhibition, endocrine
disruption, and disruption of S-adenosyl-methionine
(SAM) [Krieger, 2001]. Oxidative DNA damage can
interfere with the ability of methyl-transferases to interact
with DNA [Valinluck et al., 2004], resulting in an overall
profile of reduced methylation of cytosines at CpG sites
[Turk et al., 1995]. It has been shown that certain pesti-
cides will allow promutagenic alkylation damage to
DNA, which in turn can produce increased DNAm [Ray
and Richards, 2001]. Organophosphates, which operate
via AChE inhibition, have been found to decrease paraox-
onase activity in chronically exposed workers [Hernandez
et al., 2003]. Exposure to endocrine disruptors may pro-
mote an alteration in DNA methylation sequences, and
this is associated with the development of trans-
generational disease states [Chang et al., 2006]. Pesticide
induced alterations in SAM may affect methyl donor
availability [Shepherd et al., 2006].
Folate and vitamin B12 play important roles in DNAm
because these two cofactors are required for the synthesis
of methionine and S-adenosyl methionine (SAM), the
common methyl donor required for the maintenance of
methylation patterns in DNA [Brunaud et al., 2003].
Folate and vitamin B12 did not meet the criteria for model
covariates. However, when we stratified by plasma folate
levels, those with lower levels had higher GSTp1 promot-
er and lower LINE-1 DNAm than those with higher plas-
ma folate levels.
Cell population heterogeneity in whole blood may have
affected the findings in this study. However, DNAm levels
have been found to be highly correlated between cell frac-
tions, though there may be some regional differences
[Adalsteinsson et al., 2012]. We were unable to account
for different cell types in our study and thus were not able
to address any potential confounding related to this. We
were also unable to include the measurement of gene
expression in our study, which would be useful to evaluate
in future studies to understand more fully the impact of
altered DNAm in people with high pesticide exposures.
Another limitation of this study is that recall may have
been better among younger or more highly educated
applicators, and this may have influenced the higher
prevalence of HPEE reported in those groups. Also,
HPEE may possibly be more common in younger applica-
tors due to riskier work or behaviors at a younger age.
Since methylation alterations increase with age, and older
applicators reported fewer HPEE in our study population,
this could have driven some estimates towards the null,
though we did not find potential effect modification by
age for CDH1 and LINE-1 methylation, which had null
estimates in analyses of the total population. Since the
AHS applicators are predominantly white males, these
results may not be relevant to females or people of other
races, though race was not found to be a confounder in
this study. Although we evaluated DNAm after HPEEs
were reported, this study does not offer insight into the
timing and persistence of modifications. A strength of the
study is that it included a relatively large sample of pesti-
cide applicators from two states, Iowa and North Caroli-
na, who have a variety of farming practices and crops
grown. Therefore, these results are potentially relevant to
other farming populations.
Our study longitudinally assessed the association
between high pesticide exposures and DNAm. Our expo-
sure metric, HPEE, is a non-specific measure of pesticide
exposure, which could reflect exposure to pesticides with
different mechanisms of action. Our findings for HPEE,
which we consider a surrogate for acute, high pesticide
exposure, indicate that pesticide exposure at levels that
do not produce acute pesticide poisoning has the potential
to influence DNAm in humans in the promoter region of
GSTp1, and in some subgroups reduced DNAm in the
MGMT promoter and LINE-1. Since hypermethylation of
GSTp1 has been consistently associated with prostate can-
cer, and farmers have higher rates of prostate cancer than
the general population, the associations we found with
high pesticide exposures warrant further investigation. A
better understanding of the timing and persistence of
modifications could be ascertained via a study design that
includes serial biomarkers over time.
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CDH1 
CpG #1: chr16:68,770,944 
CpG #2: chr16:68,770,947 
CpG #3: chr16:68,770,960 
 
GSTP1 
CpG #1: chr11:67,351,089 
CpG #2: chr11:67,351,099 
CpG #3: chr11:67,351,101 
CpG #4: chr11:67,351,104 
Supplementary Table 1. Primer sequence and information 
Assay Name Sequence 
Genomic Location of the CpGs 
Human Feb. 2009 
(GRCh37/hg19) Assembly 
Annealin
g Temp. 
(oC) 
CDH1 
CDH1-F TTTGATTTTAGGTTTTAGTGAGT  
55 
CDH1-R (bio) ACCACAACCAATCAACAA  
CDH1-sp GTTTTAGTGAGTTAT   
Sequencing 
entry 
CGGCGGGGTTGGGATTCGAATTT
AGTGGA 
chr16:68,770,944-68,770,961  
GSTP1 
GSTP1-F TTTGGGAAAGAGGGAAAGGT  
50 GSTP1-R 
(bio) 
AACCTTATAAAAATAATCCC  
GSTP1-sp AGAGGGAAAGGTTTTTT   
Sequencing 
entry 
CGGTTAGTTGCGCGGCGATTTCG
GGGATTTTAGGGCGTTTTTTTGCG
GTCGACGTTCGGGGTGTAG 
chr11:67,351,089-67,351,146  
MGMT 
MGMT-F GTTGTAGTGATTGTGGATTGG  
53.9 MGMT-R 
(bio) 
CAACATAAAAAAATAAAAAAAACC
C 
 
MGMT-sp GTTGTAGTGATTGTGGATTGG   
Sequencing 
entry 
CGTGTGGCGGGGGTCGTGGTAGT
TTTT 
chr10:131,265,796-131,265,811  
Supplementary Table 1. (continued) 
 
CpG #5: chr11:67,351,110 
CpG #6: chr11:67,351,124 
CpG #7: chr11:67,351,134 
CpG #8: chr11:67,351,138 
CpG #9: chr11:67,351,141 
CpG #10: chr11:67,351,145 
 
MGMT 
CpG #1: chr10:131,265,796 
CpG #2: chr10:131,265,803 
CpG #3: chr10:131,265,810
Supplemental Table 2. Results of stratified analyses by age at blood draw, plasma folate levels, and Vitamin B12 levels via adjusted1 Linear 
Regression analyses for CDH1, MGMT, and LINE-1 and via adjusted1 Robust Regression analyses for GSTP1 
 
  N Estimate p-value  N Estimate p-value  p-interaction term  
            
  Age at blood draw    
Locus  ≤59 years  >59 years    
CDH1            
CDH1 CpG 1 (chr16:68,770,944)  269 -0.05 0.97  266 -1.33 0.38  0.53  
CDH1 CpG 2 (chr16:68,770,947)  269 0.65 0.68  265 -2.55 0.10  0.15  
CDH1 CpG 3 (chr16:68,770,960)  269 0.38 0.72  265 -0.24 0.85  0.67  
CDH1 Mean CpG 1-3   269 0.33 0.75  265 -1.41 0.23  0.26  
            
GSTp1#             
GSTp1 CpG 2 (chr11:67,351,099)   52 -0.92 0.15  54 0.53 0.64  0.87  
GSTp1 CpG 6 (chr11:67,351,124)  52 2.24 0.02  52 -0.85 0.42  0.03 * 
GSTp1 CpG 7 (chr11:67,351,134)  42 1.28 0.05  49 3.20 0.00  0.08  
GSTp1 CpG 8 (chr11:67,351,138)  38 1.23 0.40  41 3.07 0.05  0.32  
GSTp1 CpG 9 (chr11:67,351,141)  24 12.83 0.00  24 -0.96 0.64  <0.01 * 
GSTp1 CpG 10 (chr11:67,351,145)  53 0.60 0.76  57 1.54 0.13  0.82  
GSTp1 Mean CpG 2,6-10   46 0.50 0.61  43 5.65 0.00  <0.01 * 
  
          
MGMT            
MGMT CpG 1 (chr10:131,265,796)  280 0.19 0.87  273 -1.89 0.16  0.25  
MGMT CpG 2 (chr10:131,265,803)  279 1.07 0.38  273 -3.59 0.03  0.02 * 
MGMT CpG 3 (chr11:131,265,810)  278 -0.16 0.87  273 -2.55 0.05  0.11  
MGMT Mean CpG 1-3   280 0.33 0.73  273 -2.68 0.03  0.05 * 
            
LINE-1              
LINE-1 Mean  280 -0.39 0.26  273 -0.02 0.97  0.55  
            
  Plasma Folate level (ng/mL)    
  ≤16.56 ng/mL   >16.56 ng/mL    
CDH1            
CDH1 CpG 1 (chr16:68,770,944)  279 -1.42 0.30  256 0.29 0.84  0.36  
CDH1 CpG 2 (chr16:68,770,947)  278 -0.73 0.63  256 -0.63 0.70  0.92  
CDH1 CpG 3 (chr16:68,770,960)  278 -0.26 0.83  256 0.75 0.50  0.79  
CDH1 Mean CpG 1-3   278 -0.83 0.45  256 0.14 0.90  0.65  
            
GSTp1#             
GSTp1 CpG 2 (chr11:67,351,099)   51 -1.87 0.02  55 0.31 0.66  0.05 * 
GSTp1 CpG 6 (chr11:67,351,124)  50 0.52 0.81  54 0.86 0.21  0.86  
GSTp1 CpG 7 (chr11:67,351,134)  44 1.05 0.30  47 2.64 0.00  0.23  
GSTp1 CpG 8 (chr11:67,351,138)  39 1.77 0.42  40 2.69 0.06  0.80  
GSTp1 CpG 9 (chr11:67,351,141)  23 40.08 0.00  25 1.34 0.08  <0.01 * 
GSTp1 CpG 10 (chr11:67,351,145)  53 -1.53 0.40  57 2.72 0.00  0.03 * 
GSTp1 Mean CpG 2,6-10   42 13.74 0.00  47 2.90 0.00  <0.01 * 
  
          
MGMT            
MGMT CpG 1 (chr10:131,265,796)  285 -0.60 0.63  268 -0.51 0.68  0.90  
MGMT CpG 2 (chr10:131,265,803)  285 0.04 0.98  267 -1.47 0.28  0.50  
MGMT CpG 3 (chr11:131,265,810)  284 -0.72 0.49  267 -1.43 0.21  0.81  
MGMT Mean CpG 1-3   285 -0.49 0.66  268 -1.15 0.28  0.77  
            
LINE-1              
LINE-1 Mean  285 -0.69 0.05  268 0.19 0.66  0.13  
    
 
 
 
 
        
  Plasma B12 level (ng/mL)    
  ≤ 585.95 ng/mL  > 585.95 ng/mL    
CDH1            
CDH1 CpG 1 (chr16:68,770,944)  276 -1.64 0.23  259 0.23 0.87  0.34  
CDH1 CpG 2 (chr16:68,770,947)  276 -2.41 0.13  258 0.75 0.62  0.20  
CDH1 CpG 3 (chr16:68,770,960)  276 -1.13 0.32  258 1.25 0.27  0.12  
CDH1 Mean CpG 1-3   276 -1.73 0.11  258 0.71 0.52  0.13  
            
GSTp1#             
GSTp1 CpG 2 (chr11:67,351,099)   59 -1.16 0.17  47 -0.32 0.67  0.54  
GSTp1 CpG 6 (chr11:67,351,124)  59 0.81 0.40  45 0.43 0.77  0.44  
GSTp1 CpG 7 (chr11:67,351,134)  43 2.29 0.01  48 2.13 0.00  0.83  
GSTp1 CpG 8 (chr11:67,351,138)  41 -0.85 0.14  38 3.37 0.06  0.06  
GSTp1 CpG 9 (chr11:67,351,141)  25 1.41 0.23  23 0.06 0.97  0.01 * 
GSTp1 CpG 10 (chr11:67,351,145)  59 0.73 0.67  51 1.88 0.07  0.56  
GSTp1 Mean CpG 2,6-10   48 -0.02 0.98  41 2.85 0.02  0.09  
  
          
MGMT            
MGMT CpG 1 (chr10:131,265,796)  281 -1.07 0.39  272 -0.03 0.98  0.54  
MGMT CpG 2 (chr10:131,265,803)  280 -1.07 0.44  272 -0.10 0.94  0.63  
MGMT CpG 3 (chr11:131,265,810)  280 -1.98 0.06  271 -0.44 0.70  0.32  
MGMT Mean CpG 1-3   281 -1.38 0.20  272 -0.25 0.82  0.45  
            
LINE-1              
LINE-1 Mean   281 -0.66 0.10   272 0.10 0.78   0.15  
# Based on Robust Regression            
* p-value for interaction ≤0.05            
1 Adjusted for same covariates as in Linear Regressions and Robust Regressions for the total population    
 
 
